The Healthtech Podcast

How did a company go from selling luxury ties 👔 to scaling predictive hospital analytics software? This week, James is joined by Orlando Agrippa, CEO and founder of Draper and Dash, a London-based, Venture Capitalist (VC) backed healthcare AI and machine learning predictive data and analytics company. D&D leverages data from the public sector and private healthcare companies both nationally and globally and provides organisations with solutions that improve quality, safety, outcomes, efficiencies, and opportunities. Over the years D&D has worked with over 70 healthcare providers in Australia, the UK and US, helping them to drive cost improvements, form new strategic partnerships, improve health outcomes and more. Orlando has over 10 years of executive and CIO experience in the UK NHS system with relentless focus on the delivery of Clinical Systems, Business Intelligence and Analytics. Orlando spent time understanding the US healthcare system and also worked in Australia as an analytics transformation director. He has a proven track record of turnaround senior management success in both private and public sector organisations of varying scale and complexity. He has championed turnaround strategies within multimillion-pound organisations to drive up performance and visibility. Orlando is the only healthcare chartered luminary representative for Europe, with only 10 chartered luminaries globally. Orlando has Entrepreneurial experience of five acquisition, previous advisor and investor in Photodaze, M3, Bright North, Afrotherapy and Market Place City Swish.  https://www.draperanddash.com orlando.agrippa@draperanddash.com https://twitter.com/OrlandoAgrippa https://www.linkedin.com/in/orlando-agrippa-39610587/ For more information and content, check out our website www.hs.ventures. You can follow us on Twitter @HSVenture, on Instagram @hs.ventures, on Linkedin at HS. and you can email us at info@hs.live  You can get our host, Dr. James Somauroo, at www.jamessomauroo.com and you can follow him on Twitter @jamessomauroo, on Instagram @j_soms and on Linkedin at james-somauroo

This week, James is joined by Mohamed Taha, founder and CEO of Mojo Diagnostics. Mohamed has been a medical student, an engineer, an investor and is now an entrepreneur. His journey to entrepreneurship started with a misdiagnosis during his PhD in Lyon, meaning he underwent fertility testing thwart with problems and inaccuracies. This led Mohamed to explore the issue and eventually build a company to solve the worldwide problems. Mojo applies artificial intelligence to semen analysis, which is used to determine a man’s fertility. Today, diagnostic semen analysis is a very time consuming manual process requiring a highly trained professional. Using AI, Mojo is able to make the analysis easier, increasing the number of sperm that are counted and assessed. Mojo therefore assists in improving accuracy and producing reliable results, in a fraction of the time. On the podcast, James and Mohamed talk about his journey, perceptions of fertility issues, the technology needed both now and in the future and how to get investment when you’re trying to create a new market. https://www.mojo-diagnostics.com/ For more information and content, check out our website www.hs.ventures. You can follow us on Twitter @HSVenture, on Instagram @hs.ventures, on Linkedin at HS. and you can email us at info@hs.live  You can get our host, Dr. James Somauroo, at www.jamessomauroo.com and you can follow him on Twitter @jamessomauroo, on Instagram @j_soms and on Linkedin at james-somauroo

Ever wondered how a technology giant like Philips thinks about healthcare and healthtech? This week, James is joined by Jan Kimpen, Chief Medical Officer at Philips. As the leader for clinical strategy, Jan works in close collaboration with health system customers to deliver health technology solutions that support better health outcomes and experiences at lower-cost. A former hospital CEO and Professor of Paediatrics, Jan is an expert on digital innovation in healthcare with deep expertise on data management and artificial intelligence, precision medicine, telehealth and advanced homecare. Jan is also the lead spokesperson for Philips’ Future Health Index (FHI), a yearly study surveying healthcare professionals and the general populations in 15 countries to determine the readiness of nations to address global health challenges and build sustainable health systems.  Jan and James talk about Jan's career, how Philips think about healthtech startups, how they're acquiring companies and the implications of the FHI report. https://www.healthworks.philips.com/ is the Philips start-up engagement team’s webpage which includes a submission form for enabling startups to contact them. https://www.philips.com/a-w/about/news/future-health-index is the Future Health Index landing page for those keen to read up on the report. For more information and content, check out our website www.hs.ventures. You can follow us on Twitter @HSVenture, on Instagram @hs.ventures, on Linkedin at HS. and you can email us at info@hs.live  You can get our host, Dr. James Somauroo, at www.jamessomauroo.com and you can follow him on Twitter @jamessomauroo, on Instagram @j_soms and on Linkedin at james-somauroo

This week, James is joined by Dr. Yeshwanth Pulijala, artist, dentist and entrepreneur. He describes himself as a generalist who builds technologies that improve healthcare. During his PhD in VR and AR applications in healthcare, he designed and evaluated one of the first immersive virtual reality training tools for Oral and Maxillofacial Surgery. After training as a dentist, he gained over five years of interdisciplinary experience in healthcare and technology (Virtual Reality, Augmented Reality and Computer Vision). He previously built a startup (Open Simulation) to provide low-cost surgical simulation using Augmented Reality, using his understanding of healthcare challenges from a clinical point of view and building tools to address those needs. Currently, he is focused on making surgery safer through Scalpel Ltd., building a non-invasive sensing platform for hospitals to improve patient safety, prevent serious incidents and reduce costs. Their proprietary system detects and prevents errors in real-time during an operation using a combination of deep learning and sensor fusion techniques. http://scalpel.ai/ For more information and content, check out our website www.hs.ventures. You can follow us on Twitter @HSVenture, on Instagram @hs.ventures, on Linkedin at HS. and you can email us at info@hs.live  You can get our host, Dr. James Somauroo, at www.jamessomauroo.com and you can follow him on Twitter @jamessomauroo, on Instagram @j_soms and on Linkedin at james-somauroo

James is joined by Dr. Jud Brewer who holds the position of 4th most watched TED talk in 2016, with 12 million views. Jud is founder of MindSciences Inc developing digital therapeutics in the area of addiction, he is Director of Research and Innovation at the Mindfulness Center and associate professor in psychiatry at the School of Medicine at Brown University and research affiliate at MIT. He’s also held research and teaching positions at Yale University and the University of Massachusetts’ Center for Mindfulness. As an addiction psychiatrist and internationally known expert in mindfulness training for treating addictions, Dr. Jud has developed and tested novel mindfulness programs for habit change, including both in-person and app-based treatments for smoking, emotional eating, and anxiety (Eat Right Now, Unwinding Anxiety and Craving to Quit). Based on the success of these programs in the lab, he co-founded MindSciences, Inc. to create app-based digital therapeutic versions of these programs for a wider audience, working with individuals, corporations, and hospital systems to put effective, evidence-based behaviour change guidance in the hands of people struggling with unwanted behaviours and “everyday addictions.” James and Jud cover lots of topics - all of the above, plus commercialising academia, Buddhist psychology, the science of mindfulness and how to harness technology to exploit it and the do’s and don’ts of building a digital therapeutics company. https://www.drjud.com/ For more information and content, check out our website www.hs.ventures. You can follow us on Twitter @HSVenture, on Instagram @hs.ventures, on Linkedin at HS. and you can email us at info@hs.live  You can get our host, Dr. James Somauroo, at www.jamessomauroo.com and you can follow him on Twitter @jamessomauroo, on Instagram @j_soms and on Linkedin at james-somauroo

James is joined by Jake Leach, Chief Technology Officer at Dexcom. Jake oversees the development of next generation products and his teams are responsible for delivering best in class glucose monitoring technology paired with an exceptional user experience. Jake joined Dexcom in March 2004 to lead development of sensor electronics which were part of the first generation Dexcom system. Jake has served in various roles within Dexcom including Senior Vice President of R&D, Senior Director of R&D, and Manager of Engineering. From 1996 to 2004, Jake held positions in research and development at MiniMed and subsequently Medtronic Diabetes, focusing on the development of glucose sensing systems. Jake holds a Bachelor of Science degree in Electrical Engineering with a minor in Biomedical Engineering from the University of California, Los Angeles. James and Jake talk about how Jake’s background in engineering and his inquisitive mind set him up for a career in medical devices, how MiniMed and Dexcom scaled so fast and why the diabetes-tech space is so exiting right now. www.dexcom.com For more information and content, check out our website www.hs.ventures. You can follow us on Twitter @HSVenture, on Instagram @hs.ventures, on Linkedin at HS. and you can email us at info@hs.live  You can get our host, Dr. James Somauroo, at www.jamessomauroo.com and you can follow him on Twitter @jamessomauroo, on Instagram @j_soms and on Linkedin at james-somauroo

James is joined by Dr. Paul-Peter Tak, Venture Partner at Flagship Pioneering and CEO of Kintai Therapeutics. Over a more than 25-year career in the life sciences, Paul-Peter has created and led multiple companies. From 2011 until 2017, Paul-Peter founded and served as senior vice president and head of the immuno-inflammation therapy area unit at GSK. Under Paul-Peter’s leadership, this unit brought more than 10 new mechanisms of action into the clinic. From 2016 until 2018, Paul-Peter was senior vice president of R&D pipeline, chief immunology officer, development leader, and co-chair of GSK’s scientific review board. He oversaw the creation of a new portfolio of medicines in oncology, with a focus on immuno-oncology, epigenetics, and cell and gene therapy.  Trained as a general internist, rheumatologist, and immunologist, Paul-Peter has held multiple professorships and has published extensively, with more than 550 papers in his name. He served as professor of medicine and chair of the department of clinical immunology and rheumatology at the Academic Medical Centre/University of Amsterdam for twelve years. He is a professor of medicine at the Amsterdam University Medical Center, honorary professor of rheumatology at Ghent University, and honorary senior visiting fellow at the University of Cambridge. He is a fellow of the Academy of Medical Sciences in the U.K.  Paul-Peter received his medical degree cum laude from the Free University in Amsterdam and his Ph.D. from Leiden University Medical Center.  https://www.flagshippioneering.com/ For more information and content, check out our website www.hs.ventures. You can follow us on Twitter @HSVenture, on Instagram @hs.ventures, on Linkedin at HS. and you can email us at info@hs.live  You can get our host, Dr. James Somauroo, at www.jamessomauroo.com and you can follow him on Twitter @jamessomauroo, on Instagram @j_soms and on Linkedin at james-somauroo

Can we one day hack the human brain? That day might be sooner than you think... This week, James is joined by Emil Hewage, Co-Founder and CEO at BIOS. Emil undertook PhD research in computational neuroscience and machine learning at the University of Cambridge and has used this knowledge to pioneer the use of artificial intelligence for interpreting neural data. He began working in startups at age 17 and held engineering and leadership roles across a range of industries from clean energy to advanced medical technologies. He was recently named to Forbes 30 Under 30. BIOS is a leading neural engineering startup, creating the open standard hardware and software interface between the human nervous system and AI. Their team uses applied materials, machine learning, software engineering, neuroscience, and the experience of surgeons and clinicians to solve the complex problems of successfully integrating AI-based treatments into the human body. BIOS has the largest PNS neural data set in the world, performing cutting-edge machine learning research to apply this technology to chronic conditions throughout the body, enabling a new ecosystem in healthcare from delivery to recurrent care. The company was formerly known as Cambridge Bio-Augmentation Systems (CBAS) and they've recently raised $4.5 million in seed funding. https://www.bios.health/

James is joined by Gary Hughes, CEO and co-founder of Teckro. Gary founded Teckro with his brother, Nigel Hughes, and CTO Jacek Skrzypiec. Teckro uses machine learning to help get drugs and treatments to market quicker and more transparently by speeding up clinical trials - they're working with the top 10 pharmaceutical and biotech companies in the world and their platform takes pressure off doctors, nurses and drug developers and ensures treatments get to market quicker. Teckro raised $25million recently in a Series C to bring their total funding to $43 million from top VCs like Founder's Fund and Bill Maris. Their HQ is Limerick, Ireland with an engineering hub in Dublin and an office in Nashville. Teckro now has nearly  12,000 active sites worldwide and on the podcast, James and Gary talk about Teckro's growth, their funding rounds and how to innovate in clinical trials.

James is joined by Andrew Barraclough, VP of design and innovation at GlaxoSmithKline. With thirty years’ experience, Andrew Barraclough is a leading voice at the heart of design and innovation in the healthcare and FMCG sectors. Andrew joined GlaxoSmithKline in 2011, having previously worked Design Business Association, Novartis Consumer Health, Reckitt Benckiser and Pure Realisation, which he founded. As Vice President of design and innovation at GSK, Andrew has continued to push the boundaries of perception of design across 146+ markets for 25+ global brands, including Panadol, Sensodyne, Theraflu and Flonase. Andrew’s mission at GSK is to embed world class design-thinking and culture across all customer touchpoints. Andrew and James talk about the importance of design in healthtech, how to apply design thinking, the value of designers to healthtech startups and all startups need to apply design thinking from day one. https://www.gsk.com/